INTERVIEWS
BRÈVES
VRD ou KRD en première ligne ? Voici l’étude ENDURANCE avec un arrière-gout de CLARION…
D’après la communication orale de KUMAR SK et al. Carfilzomib, lenalidomide, and dexamethasone (KRd) versus bortezomib, lenalidomide, and dexamethasone (VRd) for initial therapy of newly diagnosed multiple myeloma: Results of ENDURANCE (E1A11) phase III trial. Late Breaking Abstract 3
Le myélome de haut risque en première ligne : que faire ?
D’après les communications orales de :
– Usmani SZ et al. Primary analysis of the randomized phase II trial of bortezomib, lenalidomide, dexamethasone with/without elotuzumab for newly diagnosed, high-risk multiple myeloma (SWOG-1211). Abstract 8507.
– Weisel K et al. Depth of response to isatuximab, carfilzomib, lenalidomide, and dexamethasone (Isa-KRd) in front-line treatment of high-risk multiple myeloma: Interim analysis of the GMMG-CONCEPT trial. Abstract 8508.
– Hari P et al. Long-term follow-up of BMT CTN 0702 (STaMINA) of postautologous hematopoietic cell transplantation (autoHCT) strategies in the upfront treatment of multiple myeloma (MM). Abstract 8506
Thalidomide, lénalidomide, pomalidomide et… L’iberdomide
D’après la communication orale de Richardson P et al. First-in-human phase I study of the novel CELMoD agent CC-92480 combined with dexamethasone in patients with relapsed/refractory multiple myeloma. Abstract 8500.
Le sélinexor, l’inhibiteur d’XPO1, en association dans le myélome en rechute : est-ce une bonne idée ?
D’après les communications orales de :
– Dimopoulos MA et al. Weekly selinexor, bortezomib, and dexamethasone versus twice weekly bortezomib and dexamethasone in patients with multiple myeloma after one to three prior therapies: Initial results of the phase III BOSTON study. Abstract 8501
– Gasparetto C et al. Selinexor, daratumumab, and dexamethasone in patients with relapsed/refractory multiple myeloma. Abstract 8510 (Poster 410)
Comment cibler le BCMA autrement que par des CAR T-cells ou des BiTEs ? Le Belantamab Mafodotin, l’anticorps monoclonal anti-BCMA couplé à un agent anti-microtubule
D’après la communication orale de Nooka A et al. DREAMM-6: Safety and tolerability of belantamab mafodotin in combination with bortezomib/dexamethasone in relapsed/refractory multiple myeloma. Abstract 8502.
Le vénétoclax dans le myélome… Quelques actualités à l’ASCO 2020
D’après les communications affichées de :
Kumar SK et al. Updated results from BELLINI, a phase III study of venetoclax or placebo in combination with bortezomib and dexamethasone in relapsed/refractory multiple myeloma. Abstract 8509 (Poster 409)
Kaufman J L et al. Updated analysis of a phase I/II study of venetoclax in combination with daratumumab and dexamethasone, +/- bortezomib, in patients with relapsed/refractory multiple myeloma. Abstract 8511 (Poster 411)
